Pneumocystis infectious disease

Summary

Pneumocystis infectious disease (MONDO:0005923) is a disease and 4 clinical trials. Top therapeutic interventions include clindamycin, primaquine, and atovaquone. A subtype of fungal infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Pneumocystis infectious disease
Mondo ID	MONDO:0005923
EFO	EFO:0007447
MeSH	D016720
UMLS	C0851886
MedGen	163415
Is cancer (heuristic)	no

Also known as: infections, Pneumocystis · Pneumocystis infection

Disease family

This is a subtype of fungal infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › Pneumocystis infectious disease

Related subtypes (17): cutaneous mycosis, systemic mycosis, fungal esophagitis, opportunistic mycosis, fungal gastritis, fungal lung infectious disease, sporotrichosis, fungal meningitis, fungal myositis, scedosporiosis, fungal infection of eye, mycotic endocarditis, mycotoxicosis, alternariosis, invasive scopulariopsis infection, emergomycosis, fungal discitis

Subtypes (1): pneumocystosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1
PHASE3	1
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07357103	PHASE4	NOT_YET_RECRUITING	Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)
NCT04851015	PHASE3	RECRUITING	Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
NCT06892951	PHASE1/PHASE2	NOT_YET_RECRUITING	CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia
NCT00342589	Not specified	COMPLETED	New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CLINDAMYCIN	4	3
PRIMAQUINE	4	3
ATOVAQUONE	4	1
CASPOFUNGIN	4	1
PENTAMIDINE	4	1
CHEMBL4519671	0	1
CHEMBL471792	0	1
CHEMBL4750941	0	1
CHEMBL499808	0	1